Dr. Brian LaMoreaux, MD, MS, Medical Director, Medical Affairs at Horizon Therapeutics plc discusses data presented at the 2021 European Alliance Of Associations For Rheumatology (EULAR) from the MIRROR open-label trial which looked at KRYSTEXXA® in combination with immunomodulator methotrexate in uncontrolled gout. EULAR abstract [AB0630].
Dr. Brian LaMoreaux is an internist and rheumatologist who joined Horizon Therapeutics in July 2016. He blends science and compassion in his approach to change outcomes for patients living with gout, recognizing that to change the understanding of gout, new research and continued education is required.Brian collaborates with the scientific community to push forward emerging data and to generate a foundation for new clinical studies so that clinicians may better address gout and ultimately improve outcomes for patients. Brian prioritizes having a personal impact on his community and provides one-on-one care as a volunteer clinician a free clinic in downtown Chicago.
Listen on Soundcloud.